Profile data is unavailable for this security.
About the company
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-93.72m
- Incorporated2012
- Employees28.00
- LocationViking Therapeutics Inc9920 Pacific Heights Blvd, Suite 350SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 704-4660
- Fax+1 (302) 636-5454
- Websitehttps://vikingtherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jazz Pharmaceuticals PLC | 3.83bn | 414.83m | 6.90bn | 2.80k | 18.11 | 1.85 | 6.54 | 1.80 | 6.12 | 6.12 | 53.20 | 60.03 | 0.345 | 0.6645 | 5.65 | 1,369,359.00 | 3.76 | 1.48 | 4.23 | 1.62 | 88.64 | 88.79 | 10.90 | 4.26 | 1.85 | 2.06 | 0.6048 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Exelixis Inc | 1.83bn | 207.77m | 6.92bn | 1.31k | 36.25 | 3.14 | 29.62 | 3.78 | 0.6472 | 0.6472 | 5.69 | 7.48 | 0.6087 | 2.87 | 8.09 | 1,397,105.00 | 6.91 | 8.86 | 7.85 | 9.91 | 96.04 | 96.30 | 11.35 | 15.43 | 3.30 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Bellring Brands Inc | 1.73bn | 165.20m | 7.23bn | 420.00 | 44.57 | -- | 34.28 | 4.17 | 1.24 | 1.24 | 12.99 | -2.19 | 2.39 | 5.89 | 9.62 | 4,129,762.00 | 22.78 | 18.89 | 29.01 | -- | 32.08 | 32.44 | 9.52 | 10.10 | 1.71 | 4.39 | 1.53 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
Intra-Cellular Therapies Inc | 464.37m | -139.67m | 7.58bn | 610.00 | -- | 11.70 | -- | 16.33 | -1.46 | -1.46 | 4.84 | 6.14 | 0.6262 | 1.90 | 4.91 | 761,262.30 | -18.84 | -38.27 | -21.89 | -42.77 | 92.73 | -- | -30.08 | -128.42 | 5.31 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Cerevel Therapeutics Holdings Inc | 0.00 | -432.84m | 7.76bn | 334.00 | -- | 11.50 | -- | -- | -2.66 | -2.66 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -38.29 | -- | -41.29 | -- | -- | -- | -- | -- | -- | -- | 0.3337 | -- | -- | -- | -23.14 | -- | -- | -- |
Legend Biotech Corp (ADR) | 285.14m | -518.25m | 7.96bn | 1.80k | -- | 6.36 | -- | 27.90 | -2.95 | -2.95 | 1.62 | 6.88 | 0.1794 | 9.68 | 5.70 | 158,412.80 | -32.60 | -37.71 | -38.89 | -47.19 | 49.42 | -- | -181.75 | -286.51 | 6.83 | -24.23 | 0.208 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
KBR Inc | 7.07bn | -258.00m | 8.74bn | 34.00k | -- | 6.21 | -- | 1.24 | -1.91 | -1.91 | 52.67 | 10.46 | 1.25 | -- | 5.56 | 207,970.60 | -4.45 | 0.4725 | -6.46 | 0.6678 | 13.86 | 12.18 | -3.58 | 0.4122 | -- | 1.17 | 0.5678 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
Viking Therapeutics Inc | 0.00 | -93.72m | 8.78bn | 28.00 | -- | 9.39 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Roivant Sciences Ltd | 123.24m | 4.35bn | 8.78bn | 904.00 | 2.15 | 1.44 | 2.06 | 71.27 | 5.07 | 5.23 | 0.1597 | 7.57 | 0.0259 | -- | 3.57 | 136,328.50 | 89.08 | -- | 105.17 | -- | 87.57 | -- | 3,439.02 | -- | 27.77 | -- | 0.0638 | -- | 10.84 | -- | -32.93 | -- | -- | -- |
Repligen Corp | 638.76m | 41.58m | 9.17bn | 1.78k | 227.83 | 4.65 | 83.61 | 14.35 | 0.7207 | 0.7207 | 11.27 | 35.35 | 0.2388 | 1.47 | 5.31 | 358,252.40 | 1.55 | 4.38 | 1.74 | 5.03 | 49.35 | 55.43 | 6.51 | 15.91 | 5.75 | -- | 0.2272 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
BIO-TECHNE Corp | 1.14bn | 224.12m | 9.94bn | 3.05k | 45.60 | 5.06 | 29.71 | 8.68 | 1.39 | 1.39 | 7.09 | 12.50 | 0.4495 | 2.21 | 5.84 | 375,409.50 | 8.80 | 9.57 | 9.28 | 10.20 | 67.13 | 67.35 | 19.58 | 21.91 | 3.03 | 18.86 | 0.1854 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Catalent Inc | 4.10bn | -1.30bn | 10.11bn | 17.80k | -- | 2.74 | -- | 2.47 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
United Therapeutics Corporation | 2.33bn | 984.80m | 10.39bn | 1.17k | 11.82 | 1.84 | 10.01 | 4.46 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Exact Sciences Corp | 2.50bn | -204.15m | 10.91bn | 6.50k | -- | 3.42 | 4,437.38 | 4.37 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 14.94m | 13.66% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 6.39m | 5.84% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 5.73m | 5.24% |
Viking Global Investors LPas of 31 Dec 2023 | 5.15m | 4.71% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 5.13m | 4.69% |
AllianceBernstein LPas of 31 Dec 2023 | 3.67m | 3.36% |
Balyasny Asset Management LPas of 31 Dec 2023 | 2.24m | 2.05% |
American Century Investment Management, Inc.as of 31 Dec 2023 | 2.22m | 2.03% |
Geode Capital Management LLCas of 31 Dec 2023 | 2.13m | 1.95% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.16m | 1.06% |